Four state Medicaid programs end GLP-1 obesity coverage

California, New Hampshire, Pennsylvania and South Carolina ended Medicaid coverage of GLP-1 medications for obesity treatment effective January 1, 2026, citing budget pressure ^[1][3]. The four states dropped the benefit as part of a wider retreat by state Medicaid programs from paying for weight-loss drugs ^[1][2].

KFF, the health policy research group, counted 16 state Medicaid programs covering GLP-1s for obesity as of October 2025. After the four cuts and North Carolina's December 2025 reinstatement, KFF put the number at 13 in January 2026 ^[1]. One state-by-state tracker describes the change differently, saying coverage fell from 17 states at the start of the year to 13 in early 2026; the published counts disagree on the starting figure ^[3].

The cuts apply to obesity treatment only. Under federal Medicaid rules, states must still cover GLP-1 drugs for type 2 diabetes, and for cardiovascular risk reduction (Wegovy, approved March 2024) and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, approved December 2024) ^[1]. Weight-loss drugs fall in a small group of categories that states may exclude, which is why obesity coverage is optional ^[1]. Children under 21 can still qualify for obesity treatment when it is medically necessary under Medicaid's EPSDT benefit, and Pennsylvania kept that pathway open when it ended adult coverage ^[1][4].

Cost is the stated driver. Gross Medicaid spending on GLP-1 prescriptions, for diabetes as well as weight loss, rose from about $1 billion in 2019 to almost $9 billion in 2024 ^[2], while prescriptions grew from roughly 1 million to more than 8 million over the same period ^[4]. Almost four in ten adults and a quarter of children covered by Medicaid have obesity ^[1][2].

Where coverage remains, access is usually conditional. States typically require prior authorization, and some apply BMI thresholds or step therapy that requires documented failure of other weight-loss programs first ^[1][3]. Michigan tightened its rules on January 1, 2026 to beneficiaries with a BMI of 40 or higher who have documented failure of other options, a change expected to save the state an estimated $240 million ^[2][4].

Why it matters for patients

Whether these drugs are covered depends on the diagnosis on the prescription, not only on the drug. Semaglutide is covered nationwide as Ozempic for diabetes, but covered for weight loss as Wegovy in only some states ^[1][4]. A patient whose Medicaid obesity coverage ended January 1 loses that pathway but keeps the diabetes, heart and sleep apnea pathways, still subject to prior authorization ^[1].

Medicaid enrollees pay little or no copay for prescriptions, so lower list prices do not by themselves settle access: buying the drugs directly, even at reduced prices, is likely to remain out of reach for people who qualify for Medicaid by income ^[1]. Novo Nordisk said in February 2026 that it would cut list prices for its GLP-1s to $675 per month in 2027 ^[2].

How many people lost coverage because of the January 1 cuts has not been reported. State decisions have moved in both directions: North Carolina dropped coverage in October 2025 during a budget stalemate and reinstated it in December 2025 ^[1].

What happens next

BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a five-year CMS Innovation Center model, aims to expand obesity drug access in Medicaid and Medicare through negotiated manufacturer prices. Participation is voluntary for state Medicaid programs, Medicare Part D plans and manufacturers; states and manufacturers were asked to submit their intentions by January 8, 2026, and the model is expected to begin in May 2026 ^[1]. A separate short-term demonstration is set to open Medicare Part D coverage of obesity drugs beginning July 2026, with the BALANCE model following in Part D in January 2027 ^[1].

Later reporting shows the count continuing to fall. Massachusetts ended its Medicaid weight-loss coverage on July 1, 2026, and Utah's coverage pilot ended June 30, 2026, leaving 11 states verified as covering these drugs for obesity as of July 10, 2026. Rhode Island's enacted budget restricts Medicaid coverage to type 2 diabetes starting October 1, 2026 ^[4]. Governors in Massachusetts and Rhode Island had proposed dropping weight-loss coverage from their Medicaid programs ^[2].